### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL				
MB Number:	3235-0287			
stimated average burden				
ours per response	0.5			

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person      Cheong Kwang Soo			2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RXHN]					IJ	5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)  X Director 10% Owner					
(Last) (First) (Middle) REXAHN PHARMACEUTICALS, INC., 9620 MEDICAL CENTER DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 05/01/2006						Officer (give	title below)		(specify below		
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)					_X_ For	6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(Ci	LLE, MD	(State)	(Zip)	Table I. Nan Danivative Committee Appri										
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year	) any		3. Tod (Inst	ransaction 4. S	or Disposed of tr. 3, 4 and 5)	red 5. Am (D) Owned Transa	O) Owned Following Reported Transaction(s) (Instr. 3 and 4)		neficially 6	wnership of orm: Expirect (D) (C) T Indirect (D)	Beneficial Ownership
Reminder:	Report on a	separate line for eac	h class of securities	beneficia	lly owned	direct	Persons v	who respond	quired to r				ed SEC 14	174 (9-02)
			Table II -				displays a	a currently va d of, or Benefic	cially Owne		umber.			
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transacti Code	5. Nur ion of Deriva Securi Acquii (A) or Dispos (D) (Instr.	nber tive ties red	displays a equired, Disposed ts, options, conv. 6. Date Exercisa Expiration Date (Month/Day/Ye	a currently vand of, or Beneficertible securitions and	cially Owne	ed 1		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	Ownershi Form of Derivativ Security: Direct (D or Indirect	
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transacti Code	5. Nur ion of Deriva Securi Acquii (A) or Dispos (D)	nber tive ties red	displays a equired, Dispose ts, options, convo 6. Date Exercisa Expiration Date (Month/Day/Ye  Date Exercisable	a currently vand of, or Beneficertible securitions and	7. Title and Amount of Underlying Securities	ed 1	8. Price of Derivative Security	Derivative Securities Beneficially Owned Following Reported Transaction(	Ownershi Form of Derivativ Security: Direct (D or Indirect)	of Indirect Beneficial Ownership (Instr. 4)

Reporting Owner Name / Address	Relationships					
Reporting Owner France / Francess	Director	10% Owner	Officer	Other		
Cheong Kwang Soo REXAHN PHARMACEUTICALS, INC. 9620 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850	X					

# **Signatures**

/s/ Tae Heum Jeong as attorney-in-fact for Kwang Soo Ch	eong	05/03/2006
**Signature of Reporting Person		Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Options vest on first anniversary of date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.